5-fluoro-4-methoxy-2-methyl-phenylboronic acid | 313667-11-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-fluoro-4-methoxy-2-methyl-phenylboronic acid
• 英文别名: 5-Fluoro-4-methoxy-2-methylphenylboronic acid；(5-fluoro-4-methoxy-2-methylphenyl)boronic acid
• CAS: 313667-11-7
• 化学式: C₈H₁₀BFO₃
• 分子量: 183.975
• InChiKey: CPARGBBVEBKAOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.18
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-苄氧基-4-氯-3-硝基-吡啶 、 5-fluoro-4-methoxy-2-methyl-phenylboronic acid 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 2-Benzyloxy-4-(5-fluoro-4-methoxy-2-methyl-phenyl)-3-nitro-pyridine
  参考文献：
  名称：

  作为促肾上腺皮质激素释放因子-1受体拮抗剂的吡啶并[3,2 - b ]吡嗪-3（4 H）-和蝶呤-7（8 H）-one的合成及构效关系

  摘要：

  Pyrido [3,2 - b ] pyrazin-3（4 H）-one和pteridin-7（8 H）-one被评估为促肾上腺皮质激素释放因子1受体拮抗剂。这些类似物的合成，SAR研究和药代动力学评估在本文中描述。

  DOI：

  10.1016/j.bmcl.2012.06.034

文献信息

• Substituted heterocycle fused gamma-carbolines
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：US06548493B1

  公开（公告）日：2003-04-15

  The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

  本发明涉及由结构式（I）表示的某些新化合物或其药用可接受的盐形式，其中R1、R5、R6a、R6b、R7、R8、R9、X、b、k、m和n以及虚线在此处描述。本发明还涉及包含这些新化合物作为活性成分的药物配方，以及在治疗某些疾病中使用这些新化合物及其配方。本发明的化合物是5-羟色胺激动剂和拮抗剂，在控制或预防包括肥胖、焦虑、抑郁症、精神病、精神分裂症、睡眠障碍、性功能障碍、偏头痛、头痛相关疾病、社交恐惧症以及胃肠道疾病（如胃肠道运动功能障碍）等中枢神经系统疾病方面具有用处。
• [EN] PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION<br/>[FR] PYRAZINONES PYRIDINO ET PYRIMIDINO DESTINEES AU TRAITEMENT DE L'ANXIETE ET DE LA DEPRESSION
  申请人：BRISTOL MYERS SQUIBB PHARMA CO

  公开号：WO2004031189A1

  公开（公告）日：2004-04-15

  The present invention provides compounds of Formula (I): wherein the variables A, B, Ar, R1, R2, and R3 are as defined herein. The compounds of Formula (I) can function as corticotropin releasing factor (CRF) receptor antagonists and can be useful, for example, in the treatment of disorders characterized by abnormal levels of CRF such as anxiety and depression.

  本发明提供了化合物的结构式（I）：其中变量A、B、Ar、R1、R2和R3的定义如本文所述。结构式（I）的化合物可以作为促肾上腺皮质激素释放因子（CRF）受体拮抗剂发挥作用，并且可以用于治疗由CRF异常水平引起的疾病，如焦虑和抑郁症。
• Pyridino and pyrimidino pyrazinones
  申请人：——

  公开号：US20040082784A1

  公开（公告）日：2004-04-29

  The present invention provides compounds of Formula I: 1 wherein the variables A, B, Ar, R 1 , R 2 , and R 3 are as defined herein. The compounds of Formula (I) can function as corticotropin releasing factor (CRF) receptor antagonists and can be useful, for example, in the treatment of disorders characterized by abnormal levels of CRF such as anxiety and depression.

  本发明提供了I式化合物：1其中变量A、B、Ar、R1、R2和R3的定义如本文所述。I式化合物可以作为促肾上腺皮质激素释放因子（CRF）受体拮抗剂，并可用于治疗CRF水平异常的疾病，如焦虑和抑郁症等。
• Substituted heterocyle fused gamma-carbolines
  申请人：Robichaud J. Albert

  公开号：US20060178362A1

  公开（公告）日：2006-08-10

  The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 5 , R 6a , R 6b , R 7 , R 8 , R 9 , X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

  本发明涉及用于治疗成瘾行为和睡眠障碍的化合物，其结构式表示为(I)，或其药学上可接受的盐形式，其中R1、R5、R6a、R6b、R7、R8、R9、X、b、k、m和n以及虚线如本文所述。本发明方法中使用的化合物是5-羟色胺激动剂和拮抗剂，并且对于控制或预防包括成瘾行为和睡眠障碍在内的中枢神经系统疾病是有用的。